EU‑Developed RF Balloon Catheter Enters Clinical Trials for Atrial Fibrillation

A new multielectrode radiofrequency balloon catheter with built‑in mapping, pacing, and video is now in clinical trials in Lisbon ^[1].

The device matters because atrial fibrillation affects millions worldwide, and current ablation methods can be lengthy and carry risk of collateral damage. A more accurate and faster approach could reduce procedure time, improve safety, and expand access to curative treatment.

Developed, manufactured, and tested within the European Union, the catheter combines several functions into a single balloon that inflates inside the heart chamber. The integrated mapping system creates a real‑time electrical map, while the pacing capability confirms tissue contact before energy delivery.

When activated, the catheter emits single, short radiofrequency pulses that precisely heat unhealthy tissue, creating lesions that block abnormal electrical signals. The onboard video feed lets physicians watch the balloon‑tissue interface, helping to avoid over‑ or under‑treatment.

Study activity is reported from a hospital in Lisbon, Portugal, where investigators are enrolling patients with persistent atrial fibrillation. Early data will focus on procedural success rates, safety endpoints, and the durability of the lesions compared with conventional point‑by‑point catheters.

If the trials confirm the anticipated benefits, the technology could shift the standard of care toward single‑shot ablation strategies, shortening hospital stays, and lowering overall healthcare costs. Existing catheters often require multiple applications and separate mapping equipment, increasing procedure complexity.

The research team plans to publish interim results later this year and, pending regulatory approval, seek broader rollout across European cardiac centers. Continued evaluation will determine whether the integrated design delivers the promised improvements in patient outcomes.